ARQT
Arcutis Biotherapeutics, Inc. · Healthcare · Biotechnology
动量输入(同类管理人): 持有人广度 0.0% · 股份流向 -5.4% · 净新建仓位 -6.2% · 公式
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q3 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 16.38K | $405,389 | n/a | n/a |
| Q2 2026 | 105 | +8 | 69.46M | $1.82B | +11 | −2 |
| Q1 2026 | 99 | +1 | 69.94M | $1.65B | +6 | −6 |
| Q4 2025 | 97 | +2 | 70.50M | $2.05B | +3 | n/a |
| Q3 2025 | 16 | 0 | 32.55M | $613.65M | +1 | −2 |
| Q2 2025 | 14 | -2 | 28.30M | $396.73M | n/a | −2 |
| Q1 2025 | 13 | 0 | 11.91M | $186.25M | +1 | −1 |
| Q4 2024 | 13 | +1 | 15.11M | $210.56M | +1 | n/a |
| Q3 2024 | 11 | +1 | 9.54M | $88.77M | +2 | −1 |
| Q2 2024 | 10 | n/a | 8.25M | $76.75M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 8.57M | +0.5% | $161.62M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (被动) | 7.15M | +1.4% | $134.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (被动) | 4.64M | +2.5% | $87.49M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 4.28M | n/a | $80.61M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Geode Capital Management ✦ (被动) | 2.61M | +0.9% | $49.14M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 2.12M | -2.0% | $39.94M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Goldman Sachs Group ✦ | 1.80M | n/a | $34.02M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | AQR Capital Management ✦ | 441.31K | +17.6% | $8.32M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 9 | JPMorgan Chase ✦ | 201.59K | n/a | $3.80M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 10 | Citadel Advisors ✦ | 177.27K | +21.8% | $3.34M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Fidelity (FMR) ✦ | 167.97K | +11.4% | $3.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 150.10K | -83.5% | $2.83M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 95.43K | +33.1% | $1.80M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 87.80K | +4.5% | $1.66M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Wellington Management ✦ | 46.39K | +4.8% | $874,433 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | Marshall Wace ✦ | 18.30K | 新增 | $344,955 | 0.0% | New | 1 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $344,955 | 0.0% |
已清仓
| Point72 Asset Management | $20.83M | 曾为 0.1% |
| Norges Bank | $2.45M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 267 持有人, 132.09M 股份, $3.07B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Director · 4.73K 股 · $127,325
Officer · 3.67K 股 · $91,853
Director · 4.73K 股 · $114,371
Officer · 9.99K 股 · $249,986
Director · 11.15K 股 · $279,028
Director · 27.05K 股 · $677,095
Director · 1.07K 股 · $27,912
Officer · 1.70K 股 · $45,819
Director · 4.73K 股 · $123,835
Officer · 6.70K 股 · $174,767
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论